Stock Events

Stock Events

OKYO Pharma Limited 

$1.6
12
+$0.07+4.44% Today

Statistics

Day High
1.66
Day Low
1.51
52W High
3.35
52W Low
1.09
Volume
169,289
Avg. Volume
244,120
Mkt Cap
61.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13AugExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
-0.57
-0.38
-0.19
0
Expected EPS
N/A
Actual EPS
-0.57

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.41MNet Income

Analyst Ratings

6Average Price Target
The highest estimate is 7.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OKYO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, Inc. competes in the biopharmaceutical sector focusing on ophthalmology among other areas, directly competing with OKYO's eye disease treatments.
Novartis
NVS
Mkt Cap297.35B
Novartis AG, through its ophthalmology division, competes in developing treatments for eye diseases, similar to OKYO Pharma's focus.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. has a strong presence in the pharmaceuticals market, including treatments for eye conditions that compete with OKYO's product pipeline.
Bausch Health Companies
BHC
Mkt Cap2.09B
Bausch Health Companies Inc., through its eye health products, competes directly with OKYO Pharma in the ophthalmology market.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, positioning it as a competitor to OKYO Pharma's eye disease treatments.
Biogen
BIIB
Mkt Cap25.38B
Biogen Inc. has investments in therapies for neurological conditions, some of which include ophthalmologic applications, indirectly competing with OKYO.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc. is broadly in the biopharmaceutical field with a focus on viral diseases but its expansion into other areas can position it as a competitor to OKYO.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a diverse pharmaceutical portfolio, including investments in treatments for eye diseases, making it a potential competitor to OKYO Pharma.

About

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Gary S. Jacob Ph.D.
Employees
3
Country
United Kingdom
ISIN
GG00BMFG5F62

Listings

MU
DE
OK11.MU
XNAS
US
OKYO
BOATS
BOATS
OKYO.BOATS

0 Comments

Share your thoughts

FAQ

What is OKYO Pharma Limited stock price today?▼
The current price of OKYO is $1.6 USD — it has increased by +4.44% in the past 24 hours. Watch OKYO Pharma Limited stock price performance more closely on the chart.
What is OKYO Pharma Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OKYO Pharma Limited stocks are traded under the ticker OKYO.
Is OKYO Pharma Limited stock price growing?▼
OKYO stock has risen by +0.63% compared to the previous week, the month change is a -3.01% fall, over the last year OKYO Pharma Limited has showed a +48.39% increase.
What is OKYO Pharma Limited market cap?▼
Today OKYO Pharma Limited has the market capitalization of 61.45M
What were OKYO Pharma Limited earnings last quarter?▼
OKYO earnings for the last quarter are -0.57 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OKYO Pharma Limited revenue for the last year?▼
OKYO Pharma Limited revenue for the last year amounts to 0 USD.
What is OKYO Pharma Limited net income for the last year?▼
OKYO net income for the last year is -9.41M USD.
How many employees does OKYO Pharma Limited have?▼
As of April 14, 2026, the company has 3 employees.
In which sector is OKYO Pharma Limited located?▼
OKYO Pharma Limited operates in the Health & Wellness sector.
When did OKYO Pharma Limited complete a stock split?▼
OKYO Pharma Limited has not had any recent stock splits.
Where is OKYO Pharma Limited headquartered?▼
OKYO Pharma Limited is headquartered in London, United Kingdom.